Meta-analysis of the association between MBD4 Glu346Lys polymorphism and cancer risk.

IF 1.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Journal of International Medical Research Pub Date : 2024-10-01 Epub Date: 2019-12-31 DOI:10.1177/0300060519895667

Jianguo Wang, Huaxiang Shen, Huijun Liang

{"title":"Meta-analysis of the association between MBD4 Glu346Lys polymorphism and cancer risk.","authors":"Jianguo Wang, Huaxiang Shen, Huijun Liang","doi":"10.1177/0300060519895667","DOIUrl":null,"url":null,"abstract":"Objective: The purpose of this study was to systematically evaluate the association between methyl-CpG binding domain 4, DNA glycosylase (MBD4) Glu346Lys polymorphism and cancer risk.Methods: A comprehensive document retrieval from the Chinese National Knowledge Infrastructure (CNKI), EMBASE, and PubMed databases was performed through 1 September 2019. The strength of the correlation was assessed using the pooled odds ratio (ORs) and 95% confidence interval (CIs).Results: Five relevant studies were retrieved following screening, including 1804 cases and 2193 controls. We found no association between MBD4 Glu346Lys polymorphism and cancer risk under all genetic models. Nevertheless, a subgroup analysis based on country showed a strong association in the Chinese population. Under the recessive model, Chinese individuals with the Lys/Lys genotype had a higher risk of cancer (OR = 1.37, 95% CI = 1.11-1.70).Conclusion: Analysis of the MBD4 Glu346Lys polymorphism in different populations will help to elucidate the pathogenesis of cancer. The polymorphism can be utilized as a biomarker for cancer susceptibility among Chinese people.","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504307/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/0300060519895667","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/12/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The purpose of this study was to systematically evaluate the association between methyl-CpG binding domain 4, DNA glycosylase (MBD4) Glu346Lys polymorphism and cancer risk.

Methods: A comprehensive document retrieval from the Chinese National Knowledge Infrastructure (CNKI), EMBASE, and PubMed databases was performed through 1 September 2019. The strength of the correlation was assessed using the pooled odds ratio (ORs) and 95% confidence interval (CIs).

Results: Five relevant studies were retrieved following screening, including 1804 cases and 2193 controls. We found no association between MBD4 Glu346Lys polymorphism and cancer risk under all genetic models. Nevertheless, a subgroup analysis based on country showed a strong association in the Chinese population. Under the recessive model, Chinese individuals with the Lys/Lys genotype had a higher risk of cancer (OR = 1.37, 95% CI = 1.11-1.70).

Conclusion: Analysis of the MBD4 Glu346Lys polymorphism in different populations will help to elucidate the pathogenesis of cancer. The polymorphism can be utilized as a biomarker for cancer susceptibility among Chinese people.

查看原文本刊更多论文

MBD4 Glu346Lys 多态性与癌症风险关系的元分析。

研究目的本研究旨在系统评估甲基-CpG结合域4、DNA糖基化酶（MBD4）Glu346Lys多态性与癌症风险之间的关联：截至2019年9月1日，从中国国家知识基础设施（CNKI）、EMBASE和PubMed数据库中进行了全面的文献检索。结果：经过筛选，共检索到 5 项相关研究：经过筛选，共检索到五项相关研究，包括 1804 例病例和 2193 例对照。我们发现，在所有遗传模型中，MBD4 Glu346Lys 多态性与癌症风险均无关联。然而，基于国家的亚组分析表明，在中国人群中存在很强的相关性。在隐性模型下，具有 Lys/Lys 基因型的中国人患癌症的风险更高（OR = 1.37，95% CI = 1.11-1.70）：结论：对不同人群中 MBD4 Glu346Lys 多态性的分析有助于阐明癌症的发病机制。该多态性可作为中国人癌症易感性的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of International Medical Research 医学-药学

CiteScore

3.20

自引率

0.00%

发文量

555

审稿时长

1 months

期刊介绍： _Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis. As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible. Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence. Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements. Print ISSN: 0300-0605